CompletedNot Applicable

Evaluation of Keyo in Children With Epilepsy

United Kingdom17 participantsStarted 2016-04

Plain-language summary

To evaluate the tolerance, acceptability and compliance of Keyo in 20 subjects aged 3 years and over, with intractable epilepsy or Glut-1 DS on a KD.

Who can participate

Age range3 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * 3 years and over * Confirmed diagnosis of intractable epilepsy or Glut-1 DS * Children must be currently established on a KD for at least 3 months, taken orally * Written, informed consent by participant/carer Exclusion Criteria: \-

What they're measuring

Palatability questionnaire

Timeframe: Day 8

Ease of use daily diary

Timeframe: Days 1-7

GI tolerance daily diary

Timeframe: Days 1-7

Product compliance daily diary

Timeframe: Days 1-7

Trial details

NCT IDNCT02915211

SponsorVitaflo International, Ltd

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2016-06

View on ClinicalTrials.gov More Intractable Epilepsy trials